Abstract
Etoricoxib (ET) based formulations viz. physical mixture of ET with β-cyclodextrin (CD); ethosomal formulation of ET and CD complex (DCE); and ET are investigated against skin inflammation. These formulations are characterized using XRD, SEM, TEM and DSC, revealed the amorphous nature of DCE (particle size 0.3–0.4 μm). ET with ethosome (PDE) and ET, CD with ethosome (DCE) is prepared using varied concentrations of lecithin and ethanol; demonstrated entrapment efficiencies of 70.8 ± 4.4% and 77.5 ± 4.2% for PDE-8 and DCE-8 respectively. Kneaded complex (KC) exhibited 77.96% and 75.32% drug release in 30 min in PBS pH 7.4 and 5.5 respectively. In-vitro and ex-vivo drug permeation in phosphate buffer saline (PBS) revealed 63–82% ET permeation for DCE-8; while in rat serum DCE-8 produced higher plasma concentration of ET (3.26 ± 0.25 μg/ml) within 8 h that is maintained over 24 h. The percentage inhibition of carrageenan induced paw edema, 8 h after applying DCE-8 is found to be 77.74% higher than PDE-8 (54.1%) and one more formulation which is a mixture of ET and ethanol in proper proportion (CPD) (20.04%). Stability studies indicated that DCE-8 stored at 5 ± 3 °C shows <5% change in residual drug content after 90 days. Present work clearly demonstrates that the tailor-made formulation DCE-8 may exhibit potentiality towards transdermal delivery of ET in the treatment of skin inflammation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
